EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich? copertina

EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?

EP 40 | RxSight Stock Analysis: Will a Cataract Breakthrough Make Investors Rich?

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo
 RxSight: Will a Cataract Breakthrough Make Investors Rich?AI Investment Edge · Research as of 7 November 2026. RxSight sells adjustable lenses implanted during cataract surgery and the light-delivery equipment used afterward. Can better clinical support restore repeat demand?Explore AI Consensus, AI Opinions, Profile & Fundamentals and rankings of covered assets and Strongest Buys.Four financial tests. Q3 revenue US$24.59m fell 19%; net loss widened to US$16.22m. Lens volume fell about 11% despite installed-base growth. Product gross margin improved to 73.6% from Q2’s 71.2%, but remained below 79.9% a year earlier. September cash and short-term investments were US$254.68m, including US$60m received from Alcon. Nine-month physical capex was US$3.89m; R&D expense US$27.92m is separate operating investment.The cash bridge. Nine-month operating cash +US$24.79m includes the US$60m Alcon receipt. Removing only that receipt gives US$35.21m outflow; subtracting capex gives US$39.10m outflow. This is derived arithmetic, not company normalized free cash flow or a forecast run rate. Other collaboration costs and working-capital effects remain.Fixed-date scenarios. Dated 6 November provider close US$4.54, not live Saturday. Exact weighted targets rounded to US$7.06 on 18 September 2027 and US$16.79 on 18 September 2031 imply +55.57% and +269.74% cumulative price gains using unrounded endpoints. Public delivery-rounded percentages differ slightly. No dividend is paid or assumed, so no dividend uplift. Current public weighted ratings: Strong Buy at both horizons; separate Strong Buy & Keep action. All twenty forecast steps rise, but the stock need not follow a smooth path. Bull/bear mechanisms depend on adoption, workflow, spending and development; separate unweighted stress paths are not blended into the weighted base.Alcon and the real test. US$50m of the upfront receipt became nonrefundable on 28 October. That is not another cash receipt or automatically US$50m immediate Q4 revenue. License recognition at a point in time and development recognized as it progresses are distinct; no exact Q4 recognition split is specified. Up to US$140m further milestones remain conditional; 30% royalties concern successful collaboration-product net sales under contract terms. No cash floor, automatic acquisition or immunity from dilution. Monitor recurring lens demand, product margin, operating cash consumption and development progress.The July research predates the July 6 public deal disclosure, July CEO transition and August guidance withdrawal. Those developments were already public before September; October/November commercial changes and weak latest demand are later evidence. The prior public stock was PepsiCo Episode 39, a distinct consumer-business comparison.Related conversations: Boston Scientific, Episode 25 — listen / watch; Medtronic, Episode 27 — listen / watch; GSK, Episode 36 — listen / watch. Different businesses, linked by adoption, investment and cash generation.Primary sources: Q3 results; Q3 Form 10-Q; Q2 results; July 6 update; official November presentation; research methodology. AI perspectives are correlated, not independent human analysts.Primary research conducted through the iPulse AI platform by Future Edge Group. Like, comment and subscribe. Next: Nu Holdings, known as Nubank. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit ipulseai.substack.com
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione